The story of Mikhail Blagosklonny and his advocacy of Rapamycin in 3 minutes
Is this the first time to see this name? Well, do not worry, we have curated all the important details you need to know about Mikhail Blagosklonny. He is currently an oncology professor at the Roswell Park Cancer Institute. He has been serving in this position from 15/4/2009. Before this appointment, he was a senior scientist at the Ordway Research Institute in New York. Mikhail is Oncotarget’s editor in chief.In addition to that, he sits on the editorial board of cell death and differentiation of the journal. Also, Mikhail is an associate editor of cancer therapy and biology of Oncotarget. He also doubles up as the editor in chief and the founder editor of cell cycle journal.
He attended the First Pavlov State Medical University, St. Petersburg where he graduated with an MD in internal medicine and a PhD. in cardiology and experimental medicine.Mikhail is famous for his role in TOR signaling in cancer and aging. However, he is more known for advocating the use of the drug for cancer Rapamycin that increases the days to live. Mikhail Blagosklonny has proposed the drug for anti-aging after much research on anti-aging mechanisms. He has conducted various studies on cancer and cancer therapies.There are numerous publications under Mikhail’s name. You can find more than 270 papers under his name. He has a record of having used more than twenty-five thousand citations thus holding an h-index of 83. From the above, it is clear that Mikhail is a successful scientist, physician, and professor of oncology and medicine. He has come up the ranks with many high profile appointments. Mikhail Blagosklonny is still writing more publications as the professor of oncology. He is also passionate in Bio gerontology and proposed the use of Rapamycin to prolong life on several occasions.
In the past, people believed aging to be a functional decline resulting from the accumulation of random molecular damage that no one can prevent. However, this theory was quashed by hyperactive function theory that defines aging as a continuation of growth caused by signaling pathways like Target of Rapamycin (TOR). The TOR model suggests that rapamycin together with other Rapalogs can be used in humans to reduce aging and treat diseases like cancer if used in proper doses and schedules. These can extend the lifespan in people.Currently, the study that Rapamycin can cause immunity has been making sensational headlines. Reports say that scientists and researchers could be closing on a drug that can eliminate the effects of aging among the youth and improve the health of older people. Studies have set the right stage of using Rapamycin to stop aging and improve health that may result from aging. Scientists believe it is a turning point in the world of research.In conclusion, scientists say that people die because of aging. However, after the introduction of Rapamycin, this changes. It will slow aging and age related illnesses that include cancer.